论文部分内容阅读
应用重组人类红细胞生成素治疗尿毒症输血依赖性维持性血液透析患者的贫血，疗效显著。患者治疗过程可中止输血，从而避免各种输血反应包括因输血而感染其它疾病。笔者开始应用剂量为７５～１００单位／ｋｇ，每周２～３次，维持量为其５０％，每周１次。同时肌肉注射右旋糖铁１００ｍｇ，每周１次。治疗后２个月Ｈｂ由５３±１３．１ｇ／Ｌ升至１０５±２３．４ｇ／Ｌ，Ｈｃｔ由０．１７５±０．０５４升至０．３２４±０．６４，ＲＢＣ由２．１３±０．４０×１０１２／Ｌ升至３．１３±０．６７×１０１２／Ｌ，治疗前后有明显差异（Ｐ＜０．０１）。适当控制剂量可预防重度高血压、血栓形成及动静脉内瘘阻塞等并发症。
The application of recombinant human erythropoietin in the treatment of uremic transfusion dependent hemodialysis patients with anemia, a significant effect. Patient treatment stops blood transfusions, thus avoiding any transfusion reactions including other diseases due to blood transfusions. The author began to apply doses of 75 to 100 units / kg, 2 to 3 times per week, to maintain its volume of 50%, once a week. At the same time intramuscular dextrose iron 100mg, 1 times a week. Hb increased from 53 ± 13.1 g / L to 105 ± 23.4 g / L at 2 months after treatment, Hct increased from 0.175 ± 0.054 to 0.324 ± 0.64, and RBC increased from 2.13 ± 0 .40 × 1012 / L to 3.13 ± 0.67 × 1012 / L, there was a significant difference before and after treatment (P <0.01). Appropriate dose control can prevent severe hypertension, thrombosis and arteriovenous fistula occlusion and other complications.